242 related articles for article (PubMed ID: 31312661)
1. Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer.
Zhou J; Zhao W; Wu J; Lu J; Ding Y; Wu S; Wang H; Ding D; Mo F; Zhou Z; Teng L; Chen S
Biomed Res Int; 2019; 2019():8103142. PubMed ID: 31312661
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
3. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
4. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
5. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
6. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
7. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
[TBL] [Abstract][Full Text] [Related]
8. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
9. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
[TBL] [Abstract][Full Text] [Related]
10. [Identification of neoantigens and development of antigen-specific immunotherapy].
Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
[TBL] [Abstract][Full Text] [Related]
11. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
12. [Neoantigens and Whole-Exome Sequencing].
Karasaki T; Nakajima J; Kakimi K
Gan To Kagaku Ryoho; 2016 Jul; 43(7):791-7. PubMed ID: 27431622
[TBL] [Abstract][Full Text] [Related]
13. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
14. Cancer Neoantigens.
Schumacher TN; Scheper W; Kvistborg P
Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
[TBL] [Abstract][Full Text] [Related]
15. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets.
Chen C; Liu S; Qu R; Li B
Biomed Res Int; 2020; 2020():2861240. PubMed ID: 32733937
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy targeting neoantigens.
Lu YC; Robbins PF
Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
[TBL] [Abstract][Full Text] [Related]
18. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
Rajasagi M; Shukla SA; Fritsch EF; Keskin DB; DeLuca D; Carmona E; Zhang W; Sougnez C; Cibulskis K; Sidney J; Stevenson K; Ritz J; Neuberg D; Brusic V; Gabriel S; Lander ES; Getz G; Hacohen N; Wu CJ
Blood; 2014 Jul; 124(3):453-62. PubMed ID: 24891321
[TBL] [Abstract][Full Text] [Related]
19. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
20. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
Bethune MT; Joglekar AV
Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
